

# Julien Taieb

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7159848/julien-taieb-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

264  
papers

11,387  
citations

54  
h-index

102  
g-index

310  
ext. papers

14,045  
ext. citations

5.9  
avg, IF

5.88  
L-index

#	Paper	IF	Citations
264	Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.. <i>Journal of Clinical Oncology</i> , <b>2022</b> , 40, 11-11	2.2	1
263	Circulating tumor DNA (ctDNA) in adjuvant therapy of early stage colon cancer: current status and future perspectives.. <i>Acta Oncologica</i> , <b>2022</b> , 1-8	3.2	0
262	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2022</b> , 101880	2.4	
261	Upfront progression under pembrolizumab followed by a complete response after encorafenib and cetuximab treatment in BRAF V600E-mutated and microsatellite unstable metastatic colorectal cancer patient: A case report. <i>Genes Chromosomes and Cancer</i> , <b>2022</b> , 61, 114-118	5	0
260	Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective EpiTopes-HPV01 and EpiTopes-HPV02 studies.. <i>European Journal of Cancer</i> , <b>2022</b> , 162, 138-147	7.5	1
259	The "Immunoscore" in rectal cancer: could we search quality beyond quantity of life?. <i>Oncotarget</i> , <b>2022</b> , 13, 18-31	3.3	0
258	Overall Survival and Prognostic Factors among Older Patients with Metastatic Pancreatic Cancer: A Retrospective Analysis Using a Hospital Database.. <i>Cancers</i> , <b>2022</b> , 14,	6.6	1
257	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors.. <i>JCO Precision Oncology</i> , <b>2022</b> , 6, e2100181	3.6	2
256	Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2022</b> , 101920	2.4	0
255	Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.. <i>European Journal of Cancer</i> , <b>2022</b> , 166, 100-111	7.5	1
254	Encorafenib plus cetuximab treatment in BRAF V600E-mutated metastatic colorectal cancer patients pre-treated with an anti-EGFR: An AGEO-GONO case series.. <i>European Journal of Cancer</i> , <b>2022</b> , 168, 34-40	7.5	0
253	Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin. <i>Journal of Clinical Oncology</i> , <b>2021</b> , JCO2102008	2.2	7
252	Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003. <i>Future Oncology</i> , <b>2021</b> , 17, 5013-5022	3.6	
251	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). <i>European Journal of Cancer</i> , <b>2021</b> , 159, 24-33	7.5	2
250	Bridge to surgery after irinotecan-based liver chemoembolization for metastatic gastric adenocarcinoma: Letter to the editor. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101557	2.4	
249	Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years of follow-up results of the PRODIGE 22 phase II randomized multicentre trial. <i>Colorectal Disease</i> , <b>2021</b> , 23, 1357-1369	2.1	4
248	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. <i>British Journal of Cancer</i> , <b>2021</b> , 124, 1941-1948	8.7	5

247	Acute renal failure under encorafenib, binimetinib and cetuximab for BRAF V600E-mutated colorectal cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 147, 60-62	7.5	1
246	Biomarker testing and mutation prevalence in metastatic colorectal cancer patients in five European countries using a large oncology database. <i>Future Oncology</i> , <b>2021</b> , 17, 1483-1494	3.6	4
245	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101681	2.4	
244	Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 639675	5.3	1
243	Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. <i>Future Oncology</i> , <b>2021</b> , 17, 1843-1854	3.6	2
242	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , <b>2021</b> , 43, 1201-1212	3.5	0
241	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Analysis of the PRODIGE-GERCOR IDEA-France Trial. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 5638-5646	12.9	11
240	Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. <i>Future Oncology</i> , <b>2021</b> , 17, 1977-1985	3.6	3
239	Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
238	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 4768-4780	12.9	5
237	Efficacy of Anti-EGFR in Microsatellite Instability Metastatic Colorectal Cancer Depending on Sporadic or Familial Origin. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 496-500	9.7	2
236	Clinical and Regulatory Considerations for the Use of Bevacizumab Biosimilars in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 42-51.e3	3.8	2
235	The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis. <i>CardioVascular and Interventional Radiology</i> , <b>2021</b> , 44, 50-62	2.7	4
234	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , <b>2021</b> , 11, 408-423	24.4	12
233	Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 966-977	2.2	42
232	What is the Best Therapeutic Strategy for Metachronous Resectable Colorectal Liver Metastases After Adjuvant Oxaliplatin-Based Chemotherapy? A Multidisciplinary Inter-Group Survey. <i>World Journal of Surgery</i> , <b>2021</b> , 45, 822-830	3.3	1
231	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , <b>2021</b> , 144, 101-112	7.5	4
230	Impact of the IDEA Collaboration Study Results on Clinical Practice in France for Patients With Stage III Colon Cancer: A National GERCOR - PRODIGE Survey. <i>Clinical Colorectal Cancer</i> , <b>2021</b> , 20, 79-83.e4	3.8	1

229	Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. <i>Journal of the National Cancer Institute</i> , <b>2021</b> , 113, 400-407	9.7	12
228	Real-world study of treatment patterns and outcomes among patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in Europe.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 391-391	2.2	
227	Prognostic value of the PrP-ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , <b>2021</b> , 10, 1940674	7.2	4
226	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 642-651	2.2	27
225	Comments On "A Prospective, Single-Arm, Multicenter Trial of Diverting Stoma Followed By Neoadjuvant Chemotherapy Using mFOLFOX6 for Obstructive Colon Cancer: YCOG 1305 (PROBE study)" <i>Ann Surg</i> 2020 [Epub ahead of print]. DOI: 10.1097/SLA.0000000000004494. <i>Annals of Surgery</i> , <b>2021</b> , 274, e878-e879	7.8	
224	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 318-323	3.3	4
223	Treatment with encorafenib and cetuximab of a non-anti-epidermal growth factor receptor-naive patient for BRAF V600E-mutated metastatic colon cancer. <i>European Journal of Cancer</i> , <b>2021</b> , 152, 1-3	7.5	1
222	Impact of laparoscopy on oncological outcomes after colectomy for stage III colon cancer: A post-hoc multivariate analysis from PETACC8 European randomized clinical trial. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1034-1040	3.3	0
221	Predictive factors of severe early treatment-related toxicity in patients receiving first-line treatment for metastatic colorectal cancer: Pooled analysis of 2190 patients enrolled in Fédération Francophone de Cancérologie Digestive (FFCD) trials. <i>European Journal of Cancer</i> , <b>2021</b> , 153, 40-50	7.5	
220	How I treat stage II colon cancer patients. <i>ESMO Open</i> , <b>2021</b> , 6, 100184	6	2
219	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , <b>2021</b> ,	9.7	3
218	Chemotherapy use in end-of-life digestive cancer patients: a retrospective AGEO observational study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101709	2.4	
217	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , <b>2021</b> , 13,	6.6	3
216	Atypical cutaneous metastases of poorly cohesive carcinoma of the stomach: Letter to the editor. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 46, 101795	2.4	
215	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 1254-1259	3.3	2
214	Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: An AGEO prospective multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2021</b> , 45, 101603	2.4	2
213	"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 730-733	3.3	6
212	Aflibercept in Combination With FOLFIRI as First-line Chemotherapy in Patients With Metastatic Colorectal Cancer (mCRC): A Phase II Study (FFCD 1302). <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 285-290	3.8	2

211	A comprehensive overview of promising biomarkers in stage II colorectal cancer. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 88, 102059	14.4	4
210	Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. <i>ESMO Open</i> , <b>2020</b> , 5, e000698	6	7
209	Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 518-524	8.7	5
208	Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 study. <i>Gut</i> , <b>2020</b> , 69, 681-690	19.2	42
207	Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR). <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 1702-1710	2.2	13
206	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , <b>2020</b> , 4,	3.6	4
205	A multicentre, international, observational study on transarterial chemoembolisation in colorectal cancer liver metastases: Design and rationale of CIREL. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 857-861	3.3	2
204	A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. <i>British Journal of Cancer</i> , <b>2020</b> , 123, 811-818	8.7	12
203	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de CancFologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). <i>European Journal of Cancer</i> , <b>2020</b> , 136, 25-34	7.5	3
202	Does Bead Size Affect Patient Outcome in Irinotecan-Loaded Beads Chemoembolization Plus Systemic Chemotherapy Regimens for Liver-Dominant Colorectal Cancer? Results of an Observational Study. <i>CardioVascular and Interventional Radiology</i> , <b>2020</b> , 43, 866-874	2.7	6
201	Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives. <i>Drugs</i> , <b>2020</b> , 80, 401-415	12.1	28
200	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , <b>2020</b> , 122, 957-962	8.7	2
199	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGE0 retrospective multicenter study. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 285-296	7.5	26
198	First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study. <i>ESMO Open</i> , <b>2020</b> , 5,	6	20
197	The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection. <i>Biometrical Journal</i> , <b>2020</b> , 62, 1476-1493	1.5	2
196	Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative. <i>European Journal of Cancer</i> , <b>2020</b> , 130, 63-71	7.5	7
195	Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. <i>BMC Cancer</i> , <b>2020</b> , 20, 74	4.8	1
194	Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries. <i>Pleura and Peritoneum</i> , <b>2020</b> , 5, 20190035	2	1

193	Clinicopathological and molecular biological characteristics of early-onset stage II/III colorectal adenocarcinoma: An analysis of 25 studies with 47,184 patients (pts) in the adjuvant colon cancer end points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, 4099-4099	2.2	1
192	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 301-310.e1	3.8	3
191	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 87, 102028	14.4	5
190	Efficacy and Safety of Aflibercept in Combination With Chemotherapy Beyond Second-Line Therapy in Metastatic Colorectal Carcinoma Patients: An AGEO Multicenter Study. <i>Clinical Colorectal Cancer</i> , <b>2020</b> , 19, 39-47.e5	3.8	9
189	Plasma clearance of RAS mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. <i>International Journal of Cancer</i> , <b>2020</b> , 147, 1185-1189	7.5	14
188	YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 214-220	3.3	1
187	High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer. <i>Cellular Oncology (Dordrecht)</i> , <b>2020</b> , 43, 237-247	7.2	3
186	Factors associated with anal cancer screening uptake in men who have sex with men living with HIV: a cross-sectional study. <i>European Journal of Cancer Prevention</i> , <b>2020</b> , 29, 1-6	2	4
185	Immune scores in colorectal cancer: Where are we?. <i>European Journal of Cancer</i> , <b>2020</b> , 140, 105-118	7.5	10
184	Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. <i>Lancet Oncology, The</i> , <b>2020</b> , 21, 1620-1629	21.7	55
183	The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions. <i>Oncolmmunology</i> , <b>2020</b> , 9, 1812221	7.2	5
182	Adjuvant Chemotherapy for Stage III Colon Cancer. <i>Cancers</i> , <b>2020</b> , 12,	6.6	11
181	Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , <b>2020</b> , 12, 1758835920975356	5.4	5
180	How I treat pancreatic cancer. <i>ESMO Open</i> , <b>2020</b> , 4, e000818	6	4
179	Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. <i>Gut</i> , <b>2020</b> , 69, 531-539	19.2	59
178	Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. <i>Statistical Methods in Medical Research</i> , <b>2020</b> , 29, 541-567	2.3	2
177	Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard® Tumor Regression Grade (TRG) in gastric adenocarcinoma. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 107-114	3.3	11
176	Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2020</b> , 44, 295-301	2.4	10

175	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , <b>2020</b> , 23, 73-81	7.6	40
174	Evaluation of two nutritional scores Association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study. <i>European Journal of Cancer</i> , <b>2019</b> , 119, 35-43	7.5	15
173	Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, 245-256.e5	3.8	0
172	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2019</b> , 20, 420-435	21.7	110
171	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , <b>2019</b> , 115, 97-106	7.5	15
170	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2019</b> , 43, 663-668	2.4	9
169	How best to treat older patients with metastatic colorectal cancer?. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 331-333	18.8	2
168	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. <i>British Journal of Cancer</i> , <b>2019</b> , 120, 697-702	8.7	9
167	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , <b>2019</b> , 46, 94-104	8.8	17
166	Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial. <i>Cancer Medicine</i> , <b>2019</b> , 8, 5079-5088	4.8	8
165	Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 312-317	8.7	10
164	Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGEO RASANC Study. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
163	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , <b>2019</b> , 79, 1375-1394	12.1	29
162	Exploring the best treatment options for BRAF-mutant metastatic colon cancer. <i>British Journal of Cancer</i> , <b>2019</b> , 121, 434-442	8.7	26
161	Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies. <i>Annals of Oncology</i> , <b>2019</b> , 30, 1466-1471	10.3	53
160	Carcinoembryonic Antigen Levels and Survival in Stage III Colon Cancer: Analysis of the MOSAIC and PETACC-8 Trials. <i>Cancer Epidemiology Biomarkers and Prevention</i> , <b>2019</b> , 28, 1153-1161	4	7
159	Folfirinox gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. <i>Therapeutic Advances in Gastroenterology</i> , <b>2019</b> , 12, 1756284819878660	4.7	39
158	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 3520-3520	2.2	4

157	Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 4136-4136	2.2	2
156	Analyse des infiltrats immunitaires CD3 et CD8 chez 1280 malades atteints de cancers coliques de stade III : approche par intelligence artificielle entièrement automatisée. <i>Morphologie</i> , <b>2019</b> , 103, 81	0.9	
155	Refining adjuvant therapy for non-metastatic colon cancer, new standards and perspectives. <i>Cancer Treatment Reviews</i> , <b>2019</b> , 75, 1-11	14.4	30
154	Rationale and Design of the IROCAS Study: Multicenter, International, Randomized Phase 3 Trial Comparing Adjuvant Modified (m) FOLFIRINOX to mFOLFOX6 in Patients With High-Risk Stage III (pT4 and/or N2) Colon Cancer-A UNICANCER GI-PRODIGE Trial. <i>Clinical Colorectal Cancer</i> , <b>2019</b> , 18, e69-e73	3.8	6
153	Maintenance avelumab versus continuation of first-line chemotherapy in gastric cancer: JAVELIN Gastric 100 study design. <i>Future Oncology</i> , <b>2019</b> , 15, 567-577	3.6	18
152	How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. <i>Annals of Surgical Oncology</i> , <b>2019</b> , 26, 109-117	3.1	36
151	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 408-410	3.3	8
150	Role of circulating tumor DNA in the management of patients with colorectal cancer. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2018</b> , 42, 396-402	2.4	11
149	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 305-307	3.3	10
148	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , <b>2018</b> , 14, 1629-1645	3.6	14
147	Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 1177-1188	59.2	429
146	Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2018</b> , 144, 221-225	4.9	19
145	Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. <i>Targeted Oncology</i> , <b>2018</b> , 13, 107-112	5	4
144	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , <b>2018</b> , 4, 379-383	13.4	64
143	Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Kline Prognostic Category and BRAF Mutation Status. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, 50-57.e8	3.8	5
142	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 4745-4753	12.9	14
141	Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 303-312	8.7	17
140	Beyond Primary Tumor Location and RAS/BRAF Mutational Status as Prognostic Factor in Stage III Colon Cancer-Reply. <i>JAMA Oncology</i> , <b>2018</b> , 4, 1298	13.4	8



139	Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 381-386	8.7	20
138	Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. <i>Cancer Treatment Reviews</i> , <b>2018</b> , 66, 104-113	14.4	57
137	Deep Learning and Radiomics predict complete response after neo-adjuvant chemoradiation for locally advanced rectal cancer. <i>Scientific Reports</i> , <b>2018</b> , 8, 12611	4.9	88
136	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , <b>2018</b> , 17, e617-e629	3.8	31
135	Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study. <i>British Journal of Cancer</i> , <b>2018</b> , 119, 424-428	8.7	15
134	Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracil plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1107-1107	2.2	5
133	Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 803-803	2.2	3
132	JAVELIN Gastric 100: Phase 3 trial of avelumab (anti-PD-L1) maintenance therapy versus continuation of first-line chemotherapy in patients with advanced gastric or gastroesophageal junction cancer (GC/GEJC).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS195-TPS195	2.2	12
131	Baseline characteristics in the international, open-label, early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 761-761	2.2	
130	Three fluoropyrimidine-based regimens in second-line therapy following nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer: Efficacy and tolerance in clinical practice.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 370-370	2.2	
129	5-FU or mitomycin C hepatic arterial infusion after failure of arterial oxaliplatin in patients with colorectal cancer unresectable liver metastases. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2018</b> , 42, 255-260	2.4	6
128	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , <b>2018</b> , 4, e173695	13.4	37
127	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 2452-2453	2.2	
126	Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 1469-1477	2.2	89
125	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 674-681	2.2	52
124	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). <i>Digestive and Liver Disease</i> , <b>2018</b> , 50, 1257-1271	3.3	65
123	Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. <i>ESMO Open</i> , <b>2018</b> , 3, e000353	6	30
122	Colorectal Cancer: Why Does Side Matter?. <i>Drugs</i> , <b>2018</b> , 78, 789-798	12.1	26

121	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1094-1106	21.7	61
120	Immunomodulatory Activity of VEGF in Cancer. <i>International Review of Cell and Molecular Biology</i> , <b>2017</b> , 330, 295-342	6	95
119	Outcomes in elderly patients admitted to the intensive care unit with solid tumors. <i>Annals of Intensive Care</i> , <b>2017</b> , 7, 26	8.9	24
118	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2017</b> , 2, 337-346	18.8	20
117	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. <i>European Journal of Cancer</i> , <b>2017</b> , 79, 15-22	7.5	25
116	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	138
115	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1624-1636	21.7	400
114	Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228). <i>British Journal of Cancer</i> , <b>2017</b> , 117, 965-973	8.7	12
113	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, 1159-1171	21.7	193
112	Adequate SIRT activity dose is as important as adequate chemotherapy dose - Authors Reply. <i>Lancet Oncology, The</i> , <b>2017</b> , 18, e637	21.7	1
111	Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. <i>ESMO Open</i> , <b>2017</b> , 2, e000238	6	30
110	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , <b>2017</b> , 82, 16-24	7.5	28
109	Immune therapy in colorectal cancer. <i>Colorectal Cancer</i> , <b>2017</b> , 6, 1-10	0.8	2
108	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 5416-5425	12.9	129
107	Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment. <i>Annals of Oncology</i> , <b>2017</b> , 28, iii113-iii114	10.3	2
106	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3509-3509	2.2	23
105	Association of prognostic value of primary tumor location in stage III colon cancer with RAS and BRAF mutational status.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3515-3515	2.2	3
104	Colorectal cancer (CRC) patients surveyed by 18FDGPET-CT (PET-CT): An open-label multicenter randomized trial (NCT 00624260).. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3520-3520	2.2	2

103	Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study. <i>Oncotarget</i> , <b>2017</b> , 8, 101383-101393	3.3	25
102	Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU	2.2	
101	Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer. <i>European Journal of Cancer</i> , <b>2016</b> , 68, 163-172	7.5	6
100	Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 441-5	3.3	13
99	DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer: A Secondary Analysis of the PETACC-8 Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 655-662	13.4	37
98	Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial. <i>JAMA Oncology</i> , <b>2016</b> , 2, 643-653	13.4	87
97	Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Survey Comparison of Physicians and Patients. <i>Oncologist</i> , <b>2016</b> , 21, 292-300	5.7	28
96	Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , <b>2016</b> , 15, 250-6	3.8	9
95	Efficacy of Adjuvant Chemotherapy in Colon Cancer With Microsatellite Instability: A Large Multicenter AGEO Study. <i>Journal of the National Cancer Institute</i> , <b>2016</b> , 108,	9.7	84
94	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2016</b> , 40, 154-60	2.4	27
93	Methylator phenotype in colorectal cancer: A prognostic factor or not?. <i>Critical Reviews in Oncology/Hematology</i> , <b>2016</b> , 99, 74-80	7	35
92	Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology. <i>Quality of Life Research</i> , <b>2016</b> , 25, 1713-23	3.7	25
91	Validation of the prognostic impact of lymphocyte infiltration (LI) in patients (pts) with stage III colon cancer (CC) treated with adjuvant FOLFOX+/- cetuximab: A PETACC8 translational study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 553-553	2.2	3
90	Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study. <i>BMC Cancer</i> , <b>2016</b> , 16, 823	4.8	16
89	Checkpoint inhibitors and gastrointestinal immune-related adverse events. <i>Current Opinion in Oncology</i> , <b>2016</b> , 28, 264-8	4.2	27
88	Reply to the comment on Olab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort <i>British Journal of Cancer</i> , <b>2016</b> , 114, e9	8.7	3
87	FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 801-810	21.7	494
86	Advances in management of adjuvant chemotherapy in rectal cancer: Consequences for clinical practice. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2016</b> , 40, 546-552	2.4	8

85	Unresectable liver metastases in colorectal cancer: review of current strategies. <i>Minerva Chirurgica</i> , <b>2016</b> , 71, 382-397	0.8	1
84	Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. <i>British Journal of Cancer</i> , <b>2015</b> , 113, 989-95	8.7	121
83	Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22 Suppl 3, S1196-205	3.1	55
82	Complete pathological response of unresectable liver metastases from colorectal cancer after trans-arterial chemoembolization with drug-eluting beads loaded with irinotecan (DEBIRI) and concomitant systemic FOLFOX: A case report from the FFCD 1201 trial. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2015</b> , 33, 527-531	2.4	9
81	Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial--the PRODIGE 22--ECKINOXE trial. <i>BMC Cancer</i> , <b>2015</b> , 15, 511	4.8	31
80	Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues. <i>Cancer</i> , <b>2015</b> , 121, 3290-7	6.4	77
79	Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 11428-38	5.6	149
78	Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial. <i>PLoS ONE</i> , <b>2015</b> , 10, e0125350	3.7	4
77	VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. <i>Journal of Experimental Medicine</i> , <b>2015</b> , 212, 139-48	16.6	556
76	FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. <i>Annals of Surgical Oncology</i> , <b>2015</b> , 22, 295-301	3.1	119
75	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3506-3506	2.2	2
74	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX +/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3507-3507	2.2	6
73	Masitinib plus FOLFIRI for second line treatment of metastatic colorectal cancer: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 3526-3526	2.2	2
72	Masitinib plus irinotecan for second line treatment of esophagogastric adenocarcinoma: An open label phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4027-4027	2.2	1
71	Nab paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after failure of folfirinox: Results of an AGEO multicenter prospective cohort.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4123-4123	2.2	6
70	Docetaxel, 5FU, oxaliplatin (TEFOX) in 1st line treatment of signet ring cell and/or poorly differentiated gastric adenocarcinoma: a retrospective study of AGEO.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15048-e15048	2.2	5
69	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, TPS3634-TPS3634	2.2	2
68	Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 3338-47	12.9	77

67	Immunity and squamous cell carcinoma of the anus: epidemiological, clinical and therapeutic aspects. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2014</b> , 38, 18-23	2.4	7
66	Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. <i>Gastric Cancer</i> , <b>2014</b> , 17, 341-7	7.6	15
65	Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 3116-24	7.5	22
64	Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2983-93	7.5	45
63	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 862-73	21.7	190
62	FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study. <i>BMC Cancer</i> , <b>2014</b> , 14, 441	4.8	24
61	Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2014</b> , 38, e23-6	2.4	16
60	Should mismatch repair status be determined in all stage II and III colon cancer patients?. <i>Colorectal Cancer</i> , <b>2014</b> , 3, 321-329	0.8	
59	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. <i>Journal of Cancer</i> , <b>2014</b> , 5, 425-32	4.5	28
58	Colorectal cancer and immunity: what we know and perspectives. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 3738-50	5.6	93
57	Traitement adjuvant : mise au point stades II, stades III, sujets âgés, biothérapies. <i>Oncologie</i> , <b>2014</b> , 16, 504-508	1	
56	Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. <i>Nutrition and Cancer</i> , <b>2014</b> , 66, 583-9	2.8	158
55	Control of the immune response by pro-angiogenic factors. <i>Frontiers in Oncology</i> , <b>2014</b> , 4, 70	5.3	187
54	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , <b>2014</b> , 25, 2378-2385	10.3	72
53	Chemosensitivity in ovarian metastases from gastric cancer: a case series. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, 289-95	2.4	0
52	Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 81-8	13.4	81
51	Double pancreatic and gastric adenocarcinomas: a rare association. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, e137-40	2.4	5
50	Digestive neuroendocrine tumors (DNET): the era of targeted therapies. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, 134-41	2.4	3

49	The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. <i>Current Colorectal Cancer Reports</i> , <b>2013</b> , 9, 261-269	1	82
48	Mucosal imprinting of vaccine-induced CD8+ T cells is crucial to inhibit the growth of mucosal tumors. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 172ra20	17.5	165
47	An unusual recurrence site for HCC!. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2013</b> , 37, e29-31	2.4	
46	Colon cancer mutation: prognosis/prediction--letter. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1300	12.9	3
45	Folfinirox for Locally Advanced Pancreatic Adenocarcinoma. Results of an Ageo Multicenter Prospective Study. <i>Annals of Oncology</i> , <b>2013</b> , 24, iv12	10.3	2
44	Therapeutic implications of DNA mismatch repair in adjuvant colorectal cancer chemotherapy. <i>Colorectal Cancer</i> , <b>2013</b> , 2, 51-59	0.8	1
43	VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. <i>Cancer Research</i> , <b>2013</b> , 73, 539-49	10.1	397
42	VEGFA/VEGFR2-targeted therapies prevent the VEGFA-induced proliferation of regulatory T cells in cancer. <i>Oncolmmunology</i> , <b>2013</b> , 2, e25156	7.2	25
41	Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, 3525-3525	2.2	2
40	Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests. <i>European Journal of Radiology</i> , <b>2012</b> , 81, 1413-9	4.7	11
39	O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial. <i>Annals of Oncology</i> , <b>2012</b> , 23, iv17	10.3	5
38	Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. <i>Oncolmmunology</i> , <b>2012</b> , 1, 326-333	7.2	85
37	Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3574-3574	2.2	2
36	Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2011</b> , 35, 364-74	2.4	12
35	Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. <i>PLoS ONE</i> , <b>2011</b> , 6, e14540	3.7	37
34	Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. <i>Cancer</i> , <b>2011</b> , 117, 1422-8	6.4	56
33	Nutritional status affects treatment tolerability and survival in metastatic colorectal cancer patients: results of an AGEO prospective multicenter study. <i>Oncology</i> , <b>2011</b> , 81, 395-402	3.6	56
32	Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 7470-8	12.9	68

31	Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 2255-8	5.6	14
30	Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. <i>Cancer Research</i> , <b>2009</b> , 69, 3563-9	10.1	160
29	Incidence of KRAS status in ongoing adjuvant trials in colon cancer. <i>Current Colorectal Cancer Reports</i> , <b>2009</b> , 5, 171-178	1	2
28	Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 5924-30	2.2	586
27	Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. <i>PLoS ONE</i> , <b>2009</b> , 4, e4942	3.7	286
26	The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. <i>Journal of Immunology</i> , <b>2008</b> , 180, 6477-83	5.3	41
25	Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. <i>Expert Review of Anticancer Therapy</i> , <b>2008</b> , 8, 183-9	3.5	21
24	Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. <i>Current Opinion in Oncology</i> , <b>2008</b> , 20, 454-8	4.2	14
23	Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. <i>Cancer</i> , <b>2008</b> , 112, 2733-9	6.4	116
22	Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. <i>Cancer</i> , <b>2007</b> , 109, 1384-90	6.4	161
21	Hepatocellular carcinoma (HCC): an update. <i>Seminars in Oncology</i> , <b>2007</b> , 34, S12-20	5.5	50
20	Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells. <i>Cancer Research</i> , <b>2007</b> , 67, 851-3	10.1	29
19	Dendritic cell derived-exosomes: biology and clinical implementations. <i>Journal of Leukocyte Biology</i> , <b>2006</b> , 80, 471-8	6.5	103
18	Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. <i>Journal of Immunology</i> , <b>2006</b> , 176, 2722-9	5.3	174
17	The diagnostic value of biomarkers (AshTest) for the prediction of alcoholic steato-hepatitis in patients with chronic alcoholic liver disease. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 1175-85	13.4	35
16	A novel dendritic cell subset involved in tumor immunosurveillance. <i>Nature Medicine</i> , <b>2006</b> , 12, 214-9	50.5	340
15	CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 202, 1075-85	16.6	687
14	The potential of exosomes in immunotherapy. <i>Expert Opinion on Biological Therapy</i> , <b>2005</b> , 5, 737-47	5.4	40

13	The dialogue between natural killer cells and dendritic cells. <i>International Congress Series</i> , <b>2005</b> , 1285, 169-176		
12	The potential of exosomes in immunotherapy of cancer. <i>Blood Cells, Molecules, and Diseases</i> , <b>2005</b> , 35, 111-5	2.1	36
11	IL-2 production by dendritic cells is not critical for the activation of cognate and innate effectors in draining lymph nodes. <i>European Journal of Immunology</i> , <b>2005</b> , 35, 2840-50	6.1	12
10	Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. <i>Journal of Immunology</i> , <b>2004</b> , 172, 2137-46	5.3	204
9	Exosome-based immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , <b>2004</b> , 53, 234-9	7.4	91
8	Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. <i>Journal of Clinical Investigation</i> , <b>2004</b> , 114, 379-88	15.9	218
7	Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. <i>Cancer</i> , <b>2003</b> , 98, 2664-70	6.4	62
6	Truth survival in clinical research: an evidence-based requiem?. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 888-95	8	68
5	Polymorphonuclear neutrophils are a source of hepatocyte growth factor in patients with severe alcoholic hepatitis. <i>Journal of Hepatology</i> , <b>2002</b> , 36, 342-8	13.4	47
4	Ethanol-induced inhibition of cytokine release and protein degranulation in human neutrophils. <i>Journal of Leukocyte Biology</i> , <b>2002</b> , 72, 1142-7	6.5	28
3	Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. <i>Journal of Hepatology</i> , <b>2000</b> , 32, 579-86	13.4	95
2	CYTOKINES AND ALCOHOLIC HEPATITIS. <i>Alcoholism: Clinical and Experimental Research</i> , <b>1998</b> , 22, 760-767		
1	Raised plasma soluble Fas and Fas-ligand in alcoholic liver disease. <i>Lancet, The</i> , <b>1998</b> , 351, 1930-1	4.0	73